Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Daré Bioscience ( (DARE) ) is now available.
On January 6, 2026, Daré Bioscience, Inc. made an updated corporate presentation available in the investors section of its website, simultaneously furnishing the same materials to regulators as a reference exhibit. The company emphasized that the information in the presentation and related filing was provided for informational purposes only, would not be treated as filed for liability purposes under U.S. securities laws, and would not be automatically incorporated into its other securities filings, limiting potential legal exposure and formal reliance by investors on the materials.
The most recent analyst rating on (DARE) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
Spark’s Take on DARE Stock
According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.
Daré Bioscience’s overall stock score reflects significant financial challenges, including unprofitability and negative equity, which weigh heavily on the score. However, positive momentum in technical indicators and promising developments in the product pipeline, as highlighted in the earnings call, provide some optimism. The valuation remains a concern due to ongoing losses, but strategic initiatives and potential market interest in new products offer potential upside.
To see Spark’s full report on DARE stock, click here.
More about Daré Bioscience
Average Trading Volume: 196,687
Technical Sentiment Signal: Strong Sell
Current Market Cap: $28.44M
Learn more about DARE stock on TipRanks’ Stock Analysis page.